EP0752880A4 - Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i - Google Patents

Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i

Info

Publication number
EP0752880A4
EP0752880A4 EP95916183A EP95916183A EP0752880A4 EP 0752880 A4 EP0752880 A4 EP 0752880A4 EP 95916183 A EP95916183 A EP 95916183A EP 95916183 A EP95916183 A EP 95916183A EP 0752880 A4 EP0752880 A4 EP 0752880A4
Authority
EP
European Patent Office
Prior art keywords
treatment
autoimmune diseases
oral tolerance
interferon type
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95916183A
Other languages
German (de)
English (en)
Other versions
EP0752880A1 (fr
Inventor
David A Hafler
Howard L Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of EP0752880A1 publication Critical patent/EP0752880A1/fr
Publication of EP0752880A4 publication Critical patent/EP0752880A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
EP95916183A 1994-04-08 1995-04-07 Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i Withdrawn EP0752880A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US225372 1994-04-08
PCT/US1995/004120 WO1995027499A1 (fr) 1994-04-08 1995-04-07 Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i

Publications (2)

Publication Number Publication Date
EP0752880A1 EP0752880A1 (fr) 1997-01-15
EP0752880A4 true EP0752880A4 (fr) 2000-08-09

Family

ID=22844605

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95916183A Withdrawn EP0752880A4 (fr) 1994-04-08 1995-04-07 Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i

Country Status (9)

Country Link
EP (1) EP0752880A4 (fr)
JP (1) JPH09511745A (fr)
AU (1) AU686797B2 (fr)
BR (1) BR9507451A (fr)
CA (1) CA2185353A1 (fr)
HU (1) HUT74900A (fr)
IL (1) IL113303A0 (fr)
NO (1) NO964199D0 (fr)
WO (1) WO1995027499A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US6372206B1 (en) 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
CZ122697A3 (en) * 1994-10-25 1997-09-17 Immulogic Pharma Corp Preparations and methods of treating disseminated sclerosis
JP4878664B2 (ja) * 1996-12-24 2012-02-15 バイオジェン・アイデック・エムエイ・インコーポレイテッド 安定な液体インターフェロン処方物
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
AU736282B2 (en) 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ATE367823T1 (de) 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
JPWO2004058295A1 (ja) * 2002-12-26 2006-04-27 第一アスビオファーマ株式会社 類天疱瘡治療剤
WO2008130382A2 (fr) 2006-10-31 2008-10-30 East Carolina University Protéines de fusion à base de cytokine pour le traitement de troubles immunitaires
CA2757287C (fr) * 2009-03-31 2019-09-10 East Carolina University Cytokines et neuroantigenes utilises dans le traitement de maladies immunitaires
JP6590330B2 (ja) * 2013-11-11 2019-10-16 キッコーマン株式会社 経口免疫寛容増強物質のスクリーニング方法および経口免疫寛容増強組成物
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (fr) * 1988-01-22 1989-07-26 Collagen Corporation Procédé pour supprimer la croissance de cellules normales et cancéreuses
WO1993016724A1 (fr) * 1992-02-28 1993-09-02 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0325471A1 (fr) * 1988-01-22 1989-07-26 Collagen Corporation Procédé pour supprimer la croissance de cellules normales et cancéreuses
WO1993016724A1 (fr) * 1992-02-28 1993-09-02 Autoimmune, Inc. Suppression de maladies auto-immunes par des antigenes en attente

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9527499A1 *

Also Published As

Publication number Publication date
WO1995027499A1 (fr) 1995-10-19
AU2277695A (en) 1995-10-30
EP0752880A1 (fr) 1997-01-15
CA2185353A1 (fr) 1995-10-19
BR9507451A (pt) 1997-08-05
AU686797B2 (en) 1998-02-12
IL113303A0 (en) 1995-07-31
JPH09511745A (ja) 1997-11-25
HU9602750D0 (en) 1996-11-28
NO964199L (no) 1996-10-03
NO964199D0 (no) 1996-10-03
HUT74900A (en) 1997-02-28

Similar Documents

Publication Publication Date Title
EP0773716A4 (fr) Traitement de solutions de globules rouges par des agents antiviraux
EP0754042A4 (fr) Traitement de l'atherosclerose
EP0831836A4 (fr) Intercepteurs catalytiques synthetiques de radicaux libres s'utilisant comme antioxydants dans la prevention et le traitement de maladies
EP0979074A4 (fr) Traitement ou prevention des symptomes menopausiques et de l'osteoporose
FI973163A7 (fi) Pidätyskyvyttömyyden hoitaminen käyttämällä (S)-oksibutyniiniä ja (S)- desetyylioksibutyniiniä
EP0925046A4 (fr) Formulations topiques et methodes de traitement des douleurs hemorroidales
EP0752880A4 (fr) Traitement de maladies auto-immunes utilisant la tolerance orale et/ou l'interferon de type i
FI973468L (fi) Hampaiden valkaisemiseen tai ihon ja limakalvojen sairauksien hoitoon käytettävien valmisteiden valmistusmenetelmä
EP0954300A4 (fr) Traitement prophylactique et therapeutique de la sensibilisation et de l'irritation de la peau
BR9305310A (pt) Conjunto de came e conjunto de came "S"
EP0861082A4 (fr) Traitement de l'insuffisance de la membrane tissulaire
EP0832204A4 (fr) Traitement de l'insulinoresistance
EP0506893A4 (en) Diagnosis and treatment of diseases
EP0959879A4 (fr) Therapie photodynamique pour le traitement de l'arthrose
EP0800396A4 (fr) Traitement d'etats d'hyperandrogenie
MA24169A1 (fr) Traitement de l'asthme a l'aide de la tnfr-ig
EP0755255A4 (fr) Traitement de la toxoplasmose
EP0833641A4 (fr) Traitement et prevention de maladies prostatiques
EP0679083A4 (fr) Prevention et traitement de la septicemie.
FR2765214B1 (fr) Traitement de granulat par un latex anti-desenrobage
EP0866799A4 (fr) Apolipoproteine e2 et traitement de la maladie d'alzheimer
EP0981545A4 (fr) Traitement de l'osteoporose
PL322002A1 (en) Variants of human dnase i
FR2709964B1 (fr) Compositions pharmaceutiques antivirales proposées dans le traitement du SIDA et de l'Herpès.
FI973259A0 (fi) LCK-SH2-spesifisten yhdisteiden käyttö hoidettaessa autoimmuunisairauksia ja kudossiirrännäisten hyljintää

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960912

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000627

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/17 A, 7A 61K 38/28 B, 7A 61K 38/39 B, 7A 61K 38/26 B, 7A 61K 38/21 B, 7A 61K 38/21 J, 7A 61K 38:26 J, 7A 61K 38:28 J, 7A 61K 38:39 J

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20000915